Ansell shares surge 6% on AGM and trading update

Ansell shares are up after management raised earnings guidance for the year.

| More on:
Health professional putting on gloves.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Earnings upgrade: FY26 adjusted EPS lifted to US$1.37 to US$1.49, up from US$1.33 to US$1.45, after stronger-than-expected first-quarter trading.
  • Tariffs managed: Ansell is offsetting higher US tariffs through price increases and reduced sourcing from China, thereby protecting profits.
  • Efficiency gains: The company’s productivity program has delivered $47 million in savings, with synergies from the KBU acquisition ahead of plan.

Shares in Ansell Ltd (ASX: ANN) surged on Tuesday after the personal protective equipment manufacturer delivered a better-than-expected trading update and raised its earnings outlook at its 2025 Annual General Meeting.

At the time of writing, the Ansell share price is up 6% to $36.48, with the market reacting strongly after the company raised its guidance.

Trading update

Management now expects FY26 adjusted earnings per share of US$1.37 to US$1.49, up from the previously provided range of US$1.33 to US$1.45.

The upgrade follows a solid start to the financial year for Ansell, with management reporting sales and margins tracking ahead of plan, buoyed by favourable foreign-exchange trends, lower freight costs, synergy gains from its Kimberly-Clark PPE business acquisition, and ongoing manufacturing productivity improvements

Whilst US tariffs have been a hot topic this year, Ansell has found ways to manage this shift by increasing its prices and reducing its sourcing from China, which faces higher US tariffs. Management's goal is to fully offset the impact of the tariffs through a range of measures designed to protect the bottom line.

Ansell also reported solid productivity gains as its Accelerated Productivity Investment Program (APIP) continues to deliver results. The program has generated $47 million in cost savings so far in FY25, and management is targeting $50 million in cost savings for FY26. The company is also investing in a new enterprise resource planning (ERP) system to streamline operations and unlock digital efficiencies.

The integration of Kimberly-Clark's PPE business (KBU) (Ansell's largest-ever acquisition) was completed ahead of schedule, achieving $5 million in cost synergies and prompting a lift in its FY27 synergy target from $10 million to $15 million.

Ansell also reaffirmed its $200 million on-market share buyback, with $29 million completed so far this year to date.

Foolish bottom line

After a few years of losing ground following the COVID pandemic hype, Ansell is a business that is finally finding its footing. Favourable exchange rates may have contributed to this positive trading update, but this is more than just luck.

The company is creating its own luck through disciplined price increases and operational efficiency gains. With tariff risks under control, synergies running ahead of plan, and earnings guidance upgraded, Ansell's 6% share price jump is earned.

Ansell shares are now up 30% from their tariffs-related lows from earlier this year, and investor confidence is growing once again. It looks like full steam ahead for Ansell.

Motley Fool contributor Kevin Gandiya has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Sell and buy on red cubes on a digital screen.
Technology Shares

This ASX 200 high-flyer dropped 15%, is it time to jump in?

Analysts remain positive due to the company's strong fundamentals.

Read more »

Focused man entrepreneur with glasses working, looking at laptop screen thinking about something intently while sitting in the office.
Healthcare Shares

Are CSL shares a buy after their heavy decline?

Let's see what one broker is saying about the biotech giant.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why are Telix Pharmaceuticals shares diving today?

Shares in this up-and-coming drug company are under pressure over law suits filed in the US.

Read more »

A young woman wearing a red and white striped t-shirt puts her hand to her chin and looks sideways as she wonders whether to buy ASX shares
Healthcare Shares

CSL, Sonic, and Sigma Healthcare shares: Buy, hold, or sell?

Analysts share their ratings and opinions on 3 large-cap ASX 200 healthcare stocks.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

Down 38% in a year, are CSL shares now a buy?

A leading investment expert delivers his verdict on CSL shares.

Read more »

A woman holds her hand out under a graphic hologram image of a human brain with brightly lit segments and section points.
Healthcare Shares

This Cochlear-backed ASX aspirant will be targeting an epilepsy market worth north of $1 billion

This company is looking to raise $125 million to help commercialise its epilepsy monitoring technology.

Read more »

Surgeon looking at a monitor in an operating room.
Share Market News

Is the only way up for this ASX small-cap healthcare stock?

Bigger returns could be coming for this ambitious small-cap.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Monash IVF has named a new Managing Director to help right the ship

Monash IVF has named a new leader, but she will not start in the top job for some time.

Read more »